Supplementary Tables – Generalizability of ORIENT-11 Trial Results to a US Standard of Care Cohort with Advanced Non-Small Cell Lung Cancer

Supplementary Table 1. Baseline Assessment between target US
population and ORIENT-11 SPP and PPP arms before and after Adjustmenta

Abbreviations: BMI, body mass index; ECOG PS,
Eastern Cooperative Oncology Group performance status; EB, entropy balancing;
IPW, inverse probability weighting; N, number of patients in population; n,
number of patients in the specified category; PPP, placebo+pemetrexed+platinum;
PD-L1, programmed death-ligand 1; SD, standard deviation; SPP,
sintilimab+pemetrexed+platinum; SMD, standardized mean difference between SPP
and Target US Population or between PPP and Target US
Population

* Data from Yang
et al. 2020

aAdjustment
refers to IPW (primary analysis) and EB (sensitivity analysis)

b Age was recorded at first line start date

c Duration of disease was reported from advanced
diagnosis to first line start date